SQSTM1 (sequestosome-1), commonly called p62, is a multifunctional scaffold protein that couples ubiquitin tagging, autophagosome recruitment, and stress-response signaling.[1][2] In neurodegeneration biology, p62 is best interpreted as a flux integrator: it accumulates when degradative systems fail, but it is also required for selective cargo capture and clearance when those systems work.[2:1][3] This dual role explains why p62 can appear protective in early stress adaptation yet still mark disease progression in advanced proteinopathy.
In neurons and glia, p62 participates in proteostasis triage across protein aggregation, oxidative stress, and inflammatory signaling axes.[4][5] Mechanistically, it intersects with pathways central to amyotrophic lateral sclerosis (ALS), frontotemporal degeneration (FTD), tauopathies, and related disorders where autophagy-lysosome throughput is rate-limiting.[6][7]
SQSTM1 is a modular protein with architecture that enables simultaneous signaling and cargo trafficking.
The N-terminal PB1 domain mediates p62 self-assembly and higher-order complex formation. Oligomerization supports cargo clustering and concentrates autophagy machinery around ubiquitinated substrates.[2:2][3:1]
The LC3-interacting region (LIR) directly binds Atg8-family proteins, functionally docking p62-cargo complexes to autophagosomal membranes.[1:1] This step is required for efficient selective autophagy of ubiquitinated inclusions.
The C-terminal UBA domain binds polyubiquitin chains and enables cargo selection. Disease-associated changes in p62 function can impair this recognition-to-delivery step and produce apparent "cargo capture without clearance" states.[1:2][8]
A KEAP1-interacting region allows p62 to modulate NRF2 signaling. Under stress, p62 can sequester KEAP1 and enhance antioxidant transcription programs, creating feedback between proteostasis demand and redox defense.[4:1][5:1]
p62 is a canonical selective autophagy receptor: it links ubiquitinated proteins to autophagosomes via LC3 binding.[1:3] Experimental disruption of p62 pathways increases aggregate burden and destabilizes cellular quality control.[3:2]
Static p62 abundance is not equivalent to increased autophagic activity. High p62 may indicate active adaptation or blocked degradation, depending on lysosomal throughput and LC3 flux context.[2:3][6:1] For translational studies, p62 should therefore be interpreted with orthogonal flux measurements, not as a standalone endpoint.
p62 function is dynamically tuned by post-translational modifications. Ubiquitylation can increase receptor activity for selective autophagy under ubiquitin stress, and phosphorylation-dependent regulation influences redox-signaling crosstalk and condensate behavior under stress.[4:2][9][10]
By integrating stress-signaling inputs with degradative handling, p62 sits at a proteostasis-inflammation interface. In neurodegeneration, this coupling likely contributes to self-reinforcing loops between protein accumulation and tissue injury.[7:1][11]
SQSTM1 variants have been reported in patients with FTD and FTD-ALS phenotypes.[8:1][12] Functional follow-up studies support a mechanism where mutation-linked p62 dysregulation impairs selective autophagy and anti-oxidative stress buffering.[11:1]
From an evidence-quality perspective, SQSTM1 is a contributory risk/modifier axis in many cohorts rather than a single dominant driver in most sporadic disease. That distinction matters for trial design: pathway-stratified enrollment and mechanism-proximal endpoints are more defensible than broad unselected populations.
ALS-linked TBK1 perturbations can reduce p62 phosphorylation dynamics and alter downstream autophagic handling, including effects on pathogenic protein clearance pathways.[13] This places SQSTM1 within a broader autophagy receptor-kinase network where upstream defects can phenocopy direct receptor dysfunction.
Although SQSTM1 mutations are not primary monogenic causes of classic 4R-tau syndromes, p62 pathway behavior remains biologically relevant because tau aggregation and lysosomal insufficiency converge on selective-autophagy reserve.[6:2][7:2] In this framework, p62 serves as a mechanistic bridge between aggregate burden and degradative capacity.
p62 should be modeled as a state variable, not a binary marker. Interpretation is strongest when combined with:
A therapeutic decrease in p62 can indicate improved clearance, but only if accompanied by evidence of restored substrate turnover. A decrease without cargo movement can also reflect reduced receptor competence. Conversely, a transient increase may occur during effective mobilization of stressed proteomes.
Programs targeting p62-adjacent pathways are likely most actionable in cohorts with documented autophagy-lysosome stress signatures, ALS/FTD-related proteostasis phenotypes, or molecular evidence of receptor-kinase network disruption.[8:2][11:2][13:2]
Interventions should prioritize restoration of full cargo-to-lysosome flux, not isolated reduction of p62 signal intensity.[6:5][7:3]
Targeting phosphorylation/ubiquitylation control points that tune p62 receptor activity may improve selective cargo handling in genetically sensitized contexts.[4:4][9:2][13:3]
Because p62 couples degradative stress and NRF2 biology, combination approaches that co-manage aggregate load and oxidative stress may have better mechanistic coherence than single-axis programs.[4:5][5:3][11:3]
These are tractable questions for prospective translational studies that embed mechanism-proximal biomarker panels and predefined flux interpretation rules.
Pankiv S, Clausen TH, Lamark T, et al. p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of ubiquitinated protein aggregates by autophagy. J Biol Chem. 2007. ↩︎ ↩︎ ↩︎ ↩︎
Itakura E, Kishi-Itakura C, Mizushima N. p62 Targeting to the autophagosome formation site requires self-oligomerization but not LC3 binding. J Cell Biol. 2011. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Komatsu M, Waguri S, Koike M, et al. Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell. 2007. ↩︎ ↩︎ ↩︎
Ichimura Y, Waguri S, Sou YS, et al. Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective autophagy. Mol Cell. 2013. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Jain A, Lamark T, Sjottem E, et al. p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription. J Biol Chem. 2010. ↩︎ ↩︎ ↩︎ ↩︎
Menzies FM, Fleming A, Caricasole A, et al. Autophagy and Neurodegeneration: Pathogenic Mechanisms and Therapeutic Opportunities. Neuron. 2015. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Son SM, Song H, Byun J, et al. Altered proteostasis in aging and neurodegenerative disease. Int Neurourol J. 2018. ↩︎ ↩︎ ↩︎ ↩︎
Le Ber I, Camuzat A, Guerreiro R, et al. SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neurol. 2013. ↩︎ ↩︎ ↩︎
Pan JA, Sun Y, Jiang YP, et al. Ubiquitylation of p62/sequestosome1 activates its autophagy receptor function and controls selective autophagy upon ubiquitin stress. Cell Res. 2016. ↩︎ ↩︎ ↩︎
Sun D, Wu R, Zheng J, Li P, Yu L. Requirement for p62 acetylation in the aggregation of ubiquitylated proteins under nutrient stress. Nat Commun. 2018. ↩︎
Goode A, Butler K, Long J, et al. ALS-FTLD-linked mutations of SQSTM1/p62 disrupt selective autophagy and NFE2L2/NRF2 anti-oxidative stress pathway. Autophagy. 2020. ↩︎ ↩︎ ↩︎ ↩︎
Rubino E, Rainero I, Chiò A, et al. Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry. 2014. ↩︎
Ye J, Cheung J, Gerbino V, et al. ALS-associated TBK1 variant p.G175S is defective in phosphorylation of p62 and impacts TBK1-mediated signalling and TDP-43 autophagic degradation. Hum Mol Genet. 2020. ↩︎ ↩︎ ↩︎ ↩︎